Colleen Davenport Email Address

Executive Director Regulatory Affairs

Radius Health, Inc. is a science-driven biopharmaceutical company focused on developing therapeutics for patients with osteoporosis, oncology and endocrine diseases. The Company's lead product candidate is the investigational drug abaloparatide for subcutaneous injection (abaloparatide-SC), which has completed Phase III development for potential use in the reduction of fracture risk in postmenopausal women with osteoporosis. Its abaloparatide-SC is under regulatory review in Europe. Its clinical pipeline also includes an investigational abaloparatide transdermal patch for potential use in osteoporosis, and the investigational drug RAD1901 for potential use in hormone-driven and/or hormone-resistant breast cancer, and vasomotor symptoms in postmenopausal women. Its preclinical pipeline includes RAD140, which is an orally bioavailable non-steroidal, selective androgen receptor modulator (SARM). RAD140 is under investigation for potential applications in oncology and multiple conditions.

Ph.D in Immunology and Masters in Regulatory Affairs. 20 years’ experience in the pharmaceutical industry including drug discovery and regulatory affairs. In depth experience in regulatory strategy including nonclinical and clinical development, labeling, negotiation with Health Authorities and maintenance of approved products on market. Have worked primarily in the US and EU regions, in multiple therapeutic areas including cardiovascular, oncology, immunology and endocrinology, and for a variety of products including new chemical entities, monoclonal antibodies, vaccines, gene therapy and drug-device combination products.